CardiaCare: Disruptive Atrial Fibrillation Non-Invasive Neuromodulation Therapy with a Wearable Wrist Band- a Closed Loop Approach

Worldwide, 35 million and in the US 7 million people suffer from AF. These numbers are projected to reach 70M (WW) and 11.5M (US) by 2050. Annually, Out of the 5 million new people that get atrial fibrillation annually, 650 thousand end up dying from complications such as stroke. Unbalanced autonomic nervous system (ANS) tone, and multiple premature atrial complexes (PAC) are major factors contributing to the development and progression of AFib. CardiaCare technology utilizes noninvasive peripheral neuromodulation to balance the ANS and reduce PAC load thus mediating a cardiovascular anti arrhythmic response that reduces atrial fibrillation burden. Based on analyzed ECG & HRV, our novel algorithms calculate and deliver neuromodulation stimulus to the median and ulnar nerves. The stimuli accesses intrinsic cardiac nerve plexus, vagus and cardiac nerves, affects autonomic tone (ANS) and balances sympathetic and parasympathetic outflow. This response modulates heart rate and rhythm and reduces AFib triggers and burden. The technology employs a closed loop approach involving both monitoring and therapy. This may reduce (a) the number of people dying by 30% (b) the cost per patient to the healthcare system by $20000 for atrial fibrillation related hospitalizations.

CardiaCare is lead by a team of senior and accomplished Med-tech executives, with a proven track record of several M&A deals with key strategics.

Amos Ziv, CEO; Amalia Herszkowicz, COO; Tsahi Holand, CTO; Dr. Irit Yaniv, MD; Prof. dr. H.J.G.M. Crijns; Dr.Roy Beinart, MD; Ron Sacher